|
Volumn 19, Issue 17-19, 2001, Pages 2395-2399
|
Immunotherapy of chronic hepatitis B by anti HBV vaccine: From present to future
|
Author keywords
DNA vaccine; Hepatitis B; Immunotherapy
|
Indexed keywords
ALPHA INTERFERON;
DNA VACCINE;
GAMMA INTERFERON;
HEPATITIS B ANTIGEN;
HEPATITIS B VACCINE;
IMMUNOGLOBULIN G ANTIBODY;
IMMUNOGLOBULIN M ANTIBODY;
INTERLEUKIN 12;
INTERLEUKIN 5;
LAMIVUDINE;
MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;
NUCLEOSIDE DERIVATIVE;
VIRUS DNA;
B LYMPHOCYTE;
CELLULAR IMMUNITY;
CHRONIC HEPATITIS;
CHRONIC LIVER DISEASE;
CLINICAL TRIAL;
CONFERENCE PAPER;
COST CONTROL;
DISEASE ASSOCIATION;
DISEASE CONTROL;
DISEASE SEVERITY;
DRUG COST;
DRUG EFFICACY;
ENDEMIC DISEASE;
HEPATITIS B;
HEPATITIS B VIRUS;
HUMAN;
IMMUNOGENICITY;
IMMUNOTHERAPY;
LIVER CELL CARCINOMA;
NONHUMAN;
PRIORITY JOURNAL;
T LYMPHOCYTE;
TREATMENT OUTCOME;
VACCINATION;
VIRUS CARRIER;
ANIMALS;
B-LYMPHOCYTES;
HEPATITIS B VACCINES;
HEPATITIS B, CHRONIC;
HUMANS;
IMMUNOTHERAPY;
MICE;
T-LYMPHOCYTES;
VACCINES, DNA;
VACCINES, SYNTHETIC;
|
EID: 0035925668
PISSN: 0264410X
EISSN: None
Source Type: Journal
DOI: 10.1016/S0264-410X(00)00461-8 Document Type: Conference Paper |
Times cited : (73)
|
References (30)
|